

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Matthew C. Coffey, et al. Art Unit : 1642
Serial No. : 10/076,074 Examiner : Sheela J. Huff
Filed : February 15, 2002
Title : SENSITIZATION OF CHEMOTHERAPEUTIC AGENT RESISTANT
 NEOPLASTIC CELLS WITH A VIRUS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to C.F.R. § 1.98, a copy of each newly cited document is enclosed.

Applicants submit the following reference listed on the attached form PTO-1449.

1. HIRASAWA, K. et al., Reovirus Therapy of Metastatic Cancer Models in Immune-competent Mice, on the web site of Oncolytics Biotech, Inc.
(<http://www.oncolyticsbiotech.com/022801p1.html>) (2001).

Applicants would like to take this opportunity to submit a correction for a typographical error discovered in Applicant's most recent information disclosure statement and form PTO-1449. Namely, an incorrect page number was listed for the following citation (shown corrected): Fujiwara et al., Induction of Chemosensitivity in Human Lung Cancer Cells *in Vivo* by Adenovirus-mediated Transfer of the Wild-type *p53* Gene, *Cancer Research* 54:2287-2291 (1994). A copy of said citation wherein the true and correct page numbers appear has previously been submitted.

This statement is being filed before a first Office Action on the merits, therefore no fee is required under 37 C.F.R. § 1.97(b). In the event an Office Action is mailed by the United States

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EV 321 389 173 US

April 1, 2004

Date of Deposit

Applicant : Matthew C. Coffey, et al.
Serial No. : 10/076,074
Filed : February 15, 2002
Page : 2 of 2

Attorney's Docket No.: 16596-018001


Patent and Trademark Office prior to receipt of this Supplemental Information Disclosure Statement, Applicants hereby make the statement as specified in 37 C.F.R. § 1.97(e) that the document contained herein was first cited in a communication from a foreign patent office in a counterpart foreign application within three months of the filing of this Supplemental Information Disclosure Statement. Therefore, no fee is required under 37 C.F.R. §1.97(c).

To assist the Examiner, the document is listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Should it be determined that a fee is due, please apply any charges or credits to Deposit Account No. 06-1050.


Respectfully submitted,

Date: 4-1-04



Steven G. Bacs
Reg. No. 50,736

Fish & Richardson P.C.
500 Arguello Street, Suite 500
Redwood City, California 94063
Telephone: (650) 839-5070
Facsimile: (650) 839-5071

Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
16596-018001Application No.
10/076,074**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant
Matthew C. Coffey, et al.Filing Date
February 15, 2002Group Art Unit
1642**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							


Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AQ*	HIRASAWA, K. et al., Reovirus Therapy of Metastatic Cancer Models in Immune-competent Mice, on the web site of Oncolytics Biotech, Inc. (http://www.oncolyticsbiotech.com/022801p1.html) (2001).
	AR	
	AS	
	AT	

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



[THE COMPANY](#) :: [TECHNOLOGY & PRODUCT](#) :: [CLINICAL TRIALS](#) :: [INVESTORS](#) :: [FAQ](#) :: [CONTACT US](#) :: [HOME](#)

Technology & Product

REOVIRUS THERAPY OF METASTATIC CANCER MODELS IN IMMUNE-COMPETENT MICE

Kensuke Hirasawa, Chang-Soon Yoon, Sandra G. Nishikawa, David M. Waisman, Patrick WK Lee, University of Calgary, Calgary, AB, Canada.

Reovirus selectively replicates in and destroys cancer cells with an activated Ras signaling pathway. We have previously reported that direct intratumoural injection of reovirus resulted in tumour regression in mice. The application of reovirus therapy to metastatic cancer models would be the next challenge. The objective of this study is to examine the effects of intravenous (i.v.) reovirus treatment in metastatic models of immune-competent mice. First, the maximum tolerated i.v. dose of reovirus in C3H mice was determined to be 5×10^8 plaque forming units (PFU)/mouse. Using immune-competent C3H mice implanted with ras-transformed C3H-10T1/2 cells (C3 cells) at the hind flank, i.v. administration of reovirus (4 times 5×10^8 PFU's) resulted in significant reduction of tumour volumes. Combined treatment of reovirus with cyclosporine A (50 mg/kg) or cisplatin (3.0 mg/kg) further reduced the tumour size. To determine if reovirus therapy could be applied to experimental metastasis animal models, C3-L5 cells were introduced intravenously into C3H mice, which induced rapid metastasis in the lung. Subsequent i.v. treatment with reovirus (4 times 5×10^8 PFU's) resulted in significant enhancement of survival rate of these animals. We also examined the effect of i.v. reovirus therapy in the Lewis lung carcinoma metastasis mouse model, in which removal of the primary tumour invariably leads to rapid metastasis in the lung. We found that i.v. reovirus treatment resulted in significant reduction in tumour burden in these animals (based on the number of lung metastatic foci and lung weight). In conclusion, i.v. treatment of reovirus is effective in metastatic cancer models of immune-competent animals.



March 24,
[Oncolytics](#)
[Announce](#)

March 18,
[Oncolytics](#)
[Present at](#)

Oncolytics Biotech Inc. © 2001 All rights reserved

[<< Back](#)